Citius Oncology (CTOR) Liabilities and Shareholders Equity (2022 - 2026)

Citius Oncology (CTOR) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $100.7 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 10.13% year-over-year to $100.7 million in Q1 2026; TTM through Mar 2026 was $403.3 million, a 27.84% increase from a year earlier, with the FY2025 full-year figure at $100.9 million, up 19.64% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $100.7 million, down from $110.0 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for CTOR reached as high as $110.0 million in Q4 2025 and fell as low as $47.7 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $78.2 million across 5 years, with a median of $78.5 million in 2023.
• Across the five-year window, Liabilities and Shareholders Equity declined 29.57% in 2024 and jumped 87.84% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $68.2 million in 2022, then advanced by 6.5% to $72.6 million in 2023, then grew by 24.59% to $90.5 million in 2024, then climbed by 21.54% to $110.0 million in 2025, then fell by 8.43% to $100.7 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $100.7 million in Q1 2026, $110.0 million in Q4 2025, and $100.9 million in Q3 2025.